Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Microvasc Res ; 102: 86-91, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26327581

ABSTRACT

BACKGROUND: Functional infrared imaging (fIRI) is used to provide information on circulation, thermal properties and thermoregulatory function of the cutaneous tissue in several clinical settings. OBJECTIVES: This study aims to evaluate the application of fIRI in Psoriatic Arthritis (PsA) assessment, evaluating the thermoregulatory alterations due to joint inflammation in PsA patients both in basal conditions and after a mild functional (isometric) exercise; fIRI outcomes were compared with those provided by Power Doppler Ultrasonography (PWD-US). METHODS: 10 patients with PsA and 11 healthy controls were enrolled in the study. The cutaneous temperature dynamics of 20 regions of interest located on the dominant hand were recorded by means of high-resolution thermal imaging at baseline and after a functional exercise. RESULTS: Higher temperature values and faster temperature variations characterized the PsA group compared to healthy controls, confirming that the PsA-related inflammatory state alters the normal thermal proprieties of the skin overlying inflamed joints. fIRI outcomes correlated with the PWD-US findings. CONCLUSIONS: fIRI applied to the study of the response to a functional stimulus may represent an innovative, non-invasive, and operator-independent method for the assessment of peripheral PsA.


Subject(s)
Arthritis, Psoriatic/physiopathology , Adult , Aged , Arthritis, Psoriatic/diagnostic imaging , Body Temperature Regulation , Case-Control Studies , Exercise/physiology , Female , Humans , Infrared Rays , Joints/diagnostic imaging , Joints/physiopathology , Male , Middle Aged , Skin/diagnostic imaging , Skin/physiopathology , Skin Temperature , Thermography , Ultrasonography, Doppler
2.
J Eur Acad Dermatol Venereol ; 29(10): 1913-7, 2015 Oct.
Article in English | MEDLINE | ID: mdl-25879151

ABSTRACT

BACKGROUND: The role of estrogens on moles biology remains undefined although estrogenic receptors have been found on melanocytes. It has been postulated that supraphysiological estrogen levels could promote the progression of moles to melanoma. Women undergoing controlled ovarian stimulation (COS) for assisted reproductive technologies (ART) are exposed to high levels of estrogens, produced by the ovary in response to exogenous gonadotropin administration. The aim of this study is to assess whether COS for ART may have an impact on mole structure and/or characteristics. METHODS: Women undergoing to ART for various infertility conditions were included in the study. Personal and clinical data were collected. Dermatoscopic features and scores (total dermoscopy score--TDS) were statistically compared before COS and after a 6-month follow-up period. Statistical correlation was performed between estradiol, FSH blood levels and relative variation in moles dimensions. RESULTS: A total of 46 patients were included in the study. One hundred and seventy-five melanocytic lesions from 31 patients were evaluated at both time points. Although statistically significant differences were found in mole dimension and TDS between the two time points, these differences had no relevance in the clinical setting not suggesting the need for mole excision. Moreover, the only statistically significant correlation with estradiol blood concentration on hCG administration day was found with one-axis dimensional variation. CONCLUSIONS: To our knowledge this is the first work to evaluate the effect of COS on moles. The obtained results do not support a causal relation between the supraphysiological hormone levels stimulation and worsening of clinical and dermoscopical features of moles. Further study is needed to clarify whether estrogens plays a role in melanoma.


Subject(s)
Nevus, Pigmented/pathology , Ovulation Induction , Skin Neoplasms/pathology , Adult , Chorionic Gonadotropin/administration & dosage , Dermoscopy , Estradiol/blood , Female , Follicle Stimulating Hormone/blood , Humans , Infertility, Female/therapy , Nevus, Pigmented/blood , Reproductive Control Agents/administration & dosage , Reproductive Techniques, Assisted , Skin Neoplasms/blood
3.
G Ital Dermatol Venereol ; 149(5): 505-17, 2014 Oct.
Article in English | MEDLINE | ID: mdl-25014587

ABSTRACT

Idiopathic immune myopathies (IIM) are an heterogeneous group of autoimmune muscle disorders characterized by progressive muscle involvement. Dermatomyositis (DM) is the most common form of IIM. It is a multisystem disorder characterized by symmetric proximal, extensor, inflammatory myopathy, vascular involvement and a characteristic cutaneous eruption. Six types of DM have been identified: idiopathic, juvenile (JDM), cancer-related other autoimmune diseases-related, iatrogenic DM and amyopathic DM. Cutaneous manifestations of DM are the most important aspect of this disease and can precede from several months to years muscle or systemic involvement. Three groups of signs have been described: pathognomonic, highly characteristic and compatible. Although differences exist among the different clinical presentation of skin lesions, they share common histological findings including the presence of interface dermatitis with epidermal atrophy, basement membrane degeneration, vacuolar alteration of basal keratinocytes, and dermal changes consisting of interstitial mucin deposition and a sparse lymphocytic infiltrate. DM is a serious disease; the correct evaluation of any skin lesion suggesting an early diagnosis is of utmost importance. Skin signs may, also, represent a marker of treatment efficacy even though systemic symptoms worsening may not always be followed by more severe skin lesions.


Subject(s)
Dermatomyositis/pathology , Skin/pathology , Adult , Age of Onset , Aged , Antimalarials/therapeutic use , Autoantibodies/immunology , Calcinosis/etiology , Contraindications , Dermatomyositis/chemically induced , Dermatomyositis/classification , Dermatomyositis/diagnosis , Dermatomyositis/drug therapy , Dermatomyositis/etiology , Dermatomyositis/immunology , Early Diagnosis , Exanthema/etiology , Exanthema/pathology , Humans , Immunosuppressive Agents/therapeutic use , Middle Aged , Paraneoplastic Syndromes/diagnosis , Paraneoplastic Syndromes/etiology , Paraneoplastic Syndromes/pathology , Photosensitivity Disorders/etiology , Photosensitivity Disorders/pathology , Scalp Dermatoses/etiology , Skin Diseases, Papulosquamous/diagnosis , Skin Diseases, Papulosquamous/etiology , Skin Diseases, Papulosquamous/pathology , Skin Ulcer/etiology , Ultraviolet Rays/adverse effects , Ultraviolet Therapy
4.
G Ital Dermatol Venereol ; 148(2): 209-16, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23588147

ABSTRACT

AIM: Aim of the study was to assess whether Iloprost treatment summer suspension modifies systemic cytokines levels, cutaneous thermal properties and functional response to a cold-induced stress in patients affected by systemic sclerosis (SSc). METHODS: Twenty-eight patients fulfilling the American College of Rheumatology (ACR) criteria for SSc were included in the study. Patients recorded number, duration and pain-severity of Raynaud phenomenon (RP). Pain-severity was determined by a visual analog scale. Cytokines expression and production in peripheral blood mononuclear cells and serum were evaluated by RT-PCR and ELISA assay. Basal finger temperature (Tb), distal-dorsal difference temperature (DTdd) and thermal recovery time (tr) from cold stress were measured by means of functional infrared imaging (fIR). Measurements were performed in late spring, during routine Iloprost therapy (1-3 days infusion of 0.5-2 ng/kg every month), and in late summer after a therapy-withdrawal period. RESULTS: Deterioration of SSc patients' skin thermal properties was observed in the period of therapy withdrawal (Tb reduction and tr enhancement; no DTdd differences) despite the improvement in symptoms of RP. A reduction in IL-12/23p40 gene expression was recorded after therapy withdrawal and a direct correlation between IL-12/23p40 and IL-23p19 gene expression was observed, stronger after therapy suspension. CONCLUSION: Our data suggest that Iloprost treatment summer suspension may induce the loss of the therapy beneficial effect on microcirculation despite the objective reduction of RP, thus favouring a continuous use of Iloprost in absence of severe side effects. Iloprost showed to modulate only IL-23 expression corroborating the idea that this cytokine is crucial for SSc development and progression.


Subject(s)
Cytokines/blood , Iloprost/administration & dosage , Scleroderma, Systemic/drug therapy , Scleroderma, Systemic/immunology , Vasodilator Agents/administration & dosage , Withholding Treatment , Adjuvants, Immunologic/blood , Aged , Biomarkers/blood , Cold Temperature/adverse effects , Cytokines/drug effects , Female , Humans , Iloprost/adverse effects , Interleukin-12/blood , Interleukin-23/blood , Male , Middle Aged , Pain Measurement , Raynaud Disease/etiology , Scleroderma, Systemic/blood , Seasons , Time Factors , Transforming Growth Factor beta/blood , Treatment Outcome , Tumor Necrosis Factor-alpha/blood , Vasodilator Agents/adverse effects
7.
PDA J Pharm Sci Technol ; 53(4): 186-201, 1999.
Article in English | MEDLINE | ID: mdl-10754712

ABSTRACT

In this report, we present results of a recent investigation in our laboratories demonstrated the effect of process conditions and/or drug product composition on the ability of 0.2 micron and 0.22 micron sterilizing grade filters to fully retain Ralstonia (formerly Burkholderia, formerly Pseudomonas) pickettii. R. pickettii is a opportunistic pathogen widely distributed in nature as well as clinical specimens and there have been several reports of nosocomial infections due to intrinsic manufacture-related R. pickettii contamination in filter-sterilized parenteral fluids. This study documents the penetration of 0.2 micron nylon 66 and 0.22 micron modified PVDF sterilizing grade filters by R. pickettii (grown and challenged) in a drug solution under conditions that simulated a pharmaceutical filling operation. Penetration was not observed for every filter disc tested, and this may be explained, in part, by the stochastic nature (i.e., governed by the rules of probability) of the retention mechanisms involved. Scanning electron microscopy revealed significant changes in the microorganism's size and morphology as a result of exposure to the drug solution; these changes are consistent with those reported for bacteria subjected to nutrient deprivation. The SEM analyses of R. pickettii challenge suspensions in the drug solution showed that the average cell length decreased from 1.25 +/- 0.27 microns to 0.84 +/- 0.17 micron between zero and 24 hours. In addition, significant changes were observed in the size (length) distributions, with approximately 35% of the cells at 24 hours being smaller than any cell observed at the start of the challenge. These data suggest that the significant reduction in bioburden size and morphology that occurred as a result of exposure to the drug solution may play a role in the reduced ability of the 0.2 micron and 0.22 micron filters tested in this study to retain these organisms. Under the same test conditions where penetration of 0.2/0.22 micron filters was observed, 0.1 micron rated membrane filters qualified with both B. diminuta and Acholeplasma laidlawii mycoplasma consistently provided sterile effluent. Bacterial penetration of 0.2 (or 0.22) micron sterilizing grade filters was not observed under identical test conditions with either R. pickettii in a standardized solution (saline lactose broth) routinely used in challenge testing filters, or with the standard test organism, B. diminuta, in the drug solution. This study thus supports the renewed emphasis on both product- and process specific validation as well as routine bioburden monitoring expressed by regulatory agencies, and the use of enhanced bacterial removal efficiency 0.1 micron rated filters to provide enhanced sterility assurance in pharmaceutical processes.


Subject(s)
Drug Contamination/prevention & control , Sterilization/methods , Ultrafiltration/methods , Bacteria , Drug Compounding , Membranes, Artificial
SELECTION OF CITATIONS
SEARCH DETAIL
...